APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector-Based Cell & Gene Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Viral Vector-Based Cell & Gene Therapy CDMO Industry Growth and Trends Forecast to 2032

15 April 202686 pages

Choose your research edition.

Industry ResearchViral Vector-Based Cell & Gene Therapy CDMO Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector-Based Cell & Gene Therapy CDMO Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Viral Vector-Based Cell & Gene Therapy CDMO Market Analysis and Forecast 2026-2032229 pages · $4,950 USD

Market perspective

According to APO Research, the global Viral Vector-Based Cell & Gene Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Viral Vector-Based Cell & Gene Therapy CDMO market include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco and Exothera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Viral Vector-Based Cell & Gene Therapy CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Viral Vector-Based Cell & Gene Therapy CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Viral Vector-Based Cell & Gene Therapy CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Viral Vector-Based Cell & Gene Therapy CDMO.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Viral Vector-Based Cell & Gene Therapy CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Viral Vector-Based Cell & Gene Therapy CDMO Market by Company

AGC Biologics

Lonza

Charles River Laboratories

Thermo Fisher Scientific

SK pharmteco

Exothera

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type

Adeno-associated Viral

Adenoviral

Lentiviral

Retroviral

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application

Gene Therapy

Cell Therapy

Vaccine Development

Viral Vector-Based Cell & Gene Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector-Based Cell & Gene Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector-Based Cell & Gene Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector-Based Cell & Gene Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2021-2026) Table 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2027-2032) Table 6. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2026) Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share Forecasted by Type (2027-2032) Table 11. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2026) Table 24. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share Forecasted by Application (2027-2032) Table 26. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends Table 37. Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers Table 38. Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges Table 39. Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints Table 40. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Market Share by Company (2021-2026) Table 42. Global Viral Vector-Based Cell & Gene Therapy CDMO Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Viral Vector-Based Cell & Gene Therapy CDMO Key Company Headquarters & Area Served Table 44. Global Viral Vector-Based Cell & Gene Therapy CDMO Company, Product Type & Application Table 45. Global Viral Vector-Based Cell & Gene Therapy CDMO Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Viral Vector-Based Cell & Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. AGC Biologics Company Information Table 49. AGC Biologics Business Overview Table 50. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 52. AGC Biologics Recent Development Table 53. Lonza Company Information Table 54. Lonza Business Overview Table 55. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 57. Lonza Recent Development Table 58. Charles River Laboratories Company Information Table 59. Charles River Laboratories Business Overview Table 60. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 62. Charles River Laboratories Recent Development Table 63. Thermo Fisher Scientific Company Information Table 64. Thermo Fisher Scientific Business Overview Table 65. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 67. Thermo Fisher Scientific Recent Development Table 68. SK pharmteco Company Information Table 69. SK pharmteco Business Overview Table 70. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 72. SK pharmteco Recent Development Table 73. Exothera Company Information Table 74. Exothera Business Overview Table 75. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio Table 77. Exothera Recent Development Table 78. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 79. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 80. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2026) Table 81. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 82. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Country (2027-2032) Table 83. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 84. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 85. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2026) Table 86. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 87. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Country (2027-2032) Table 88. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 90. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2026) Table 91. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Country (2027-2032) Table 93. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 95. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2026) Table 96. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Country (2027-2032) Table 98. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026) & (US$ Million) Table 100. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2026) Table 101. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share Forecast by Country (2027-2032) Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Viral Vector-Based Cell & Gene Therapy CDMO Product Image Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 5. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region: 2025 VS 2032 Figure 6. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Region (2021-2032) Figure 7. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Adeno-associated Viral Image Figure 13. Global Adeno-associated Viral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Adenoviral Image Figure 15. Global Adenoviral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Lentiviral Image Figure 17. Global Lentiviral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Retroviral Image Figure 19. Global Retroviral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Type 2025 VS 2032 Figure 22. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032) Figure 23. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032) Figure 25. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Type (2021-2032) Figure 27. Gene Therapy Image Figure 28. Global Gene Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Cell Therapy Image Figure 30. Global Cell Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Vaccine Development Image Figure 32. Global Vaccine Development Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Application 2025 VS 2032 Figure 35. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032) Figure 36. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032) Figure 38. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 45. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 48. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 51. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 54. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno-associated Viral
  • Adenoviral
  • Lentiviral
  • Retroviral
Applications
  • Gene Therapy
  • Cell Therapy
  • Vaccine Development
Companies covered
  • AGC Biologics
  • Lonza
  • Charles River Laboratories
  • Thermo Fisher Scientific
  • SK pharmteco
  • Exothera

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2032)
  5. 1.4.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2021-2026)
  6. 1.4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Region (2027-2032)
  7. 1.5 Key Regions Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
  8. 1.5.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (2021-2032)
2 Viral Vector-Based Cell & Gene Therapy CDMO Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Adeno-associated Viral
  3. 2.1.2 Adenoviral
  4. 2.1.3 Lentiviral
  5. 2.1.4 Retroviral
  6. 2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Type
  7. 2.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Regions
  11. 2.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Type (2021-2026)
3 Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Gene Therapy
  3. 3.1.2 Cell Therapy
  4. 3.1.3 Vaccine Development
  5. 3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Application
  6. 3.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Regions
  10. 3.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
  2. 4.2 Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
  3. 4.3 Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
  4. 4.4 Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Viral Vector-Based Cell & Gene Therapy CDMO Revenue (2021-2026)
  2. 5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Key Company Headquarters & Area Served
  4. 5.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Company, Product Type & Application
  5. 5.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Viral Vector-Based Cell & Gene Therapy CDMO Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Viral Vector-Based Cell & Gene Therapy CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 AGC Biologics
  2. 6.1.1 AGC Biologics Company Information
  3. 6.1.2 AGC Biologics Business Overview
  4. 6.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  6. 6.1.5 AGC Biologics Recent Developments
  7. 6.2 Lonza
  8. 6.2.1 Lonza Company Information
  9. 6.2.2 Lonza Business Overview
  10. 6.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  12. 6.2.5 Lonza Recent Developments
  13. 6.3 Charles River Laboratories
  14. 6.3.1 Charles River Laboratories Company Information
  15. 6.3.2 Charles River Laboratories Business Overview
  16. 6.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  18. 6.3.5 Charles River Laboratories Recent Developments
  19. 6.4 Thermo Fisher Scientific
  20. 6.4.1 Thermo Fisher Scientific Company Information
  21. 6.4.2 Thermo Fisher Scientific Business Overview
  22. 6.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  24. 6.4.5 Thermo Fisher Scientific Recent Developments
  25. 6.5 SK pharmteco
  26. 6.5.1 SK pharmteco Company Information
  27. 6.5.2 SK pharmteco Business Overview
  28. 6.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  30. 6.5.5 SK pharmteco Recent Developments
  31. 6.6 Exothera
  32. 6.6.1 Exothera Company Information
  33. 6.6.2 Exothera Business Overview
  34. 6.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
  36. 6.6.5 Exothera Recent Developments
7 North America
  1. 7.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  3. 7.3 North America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  3. 8.3 Europe Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  3. 10.3 South America Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst